Kite’s Yescarta Receives the US FDA’s Approval for R/R Follicular Lymphoma

 Kite’s Yescarta Receives the US FDA’s Approval for R/R Follicular Lymphoma

Kite’s Yescarta Receives the US FDA’s Approval for R/R Follicular Lymphoma

Shots:

  • The approval is based on a P-II ZUMA-5 study assessing Yescarta (axicabtagene ciloleucel) in 146 patients aged ≥18rs. with r/r iNHL, prior treated with at least 2L of systemic therapy
  • The P-II ZUMA-5 study showed 91% of patients responded to a single infusion of Yescarta, including ~74% of patients in a continued remission @18mos.; mDoR was not yet reached @median follow-up of 14.5 mos. In the safety analysis, grade 3 or higher CRS and neurologic toxicities occurred in 8% and 21% of patients respectively
  • Yescarta is the first CAR T-cell therapy approved for indolent follicular lymphoma, follows FDA’s BTD and PR and marks the third approved indication for the therapy

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Businesswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post